Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 'Cellular Age' test predict lung problems in preemies?

NCT ID NCT03540680

Knowledge-focused Sponsor: Centre Hospitalier Intercommunal Creteil Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examined whether a marker of cellular aging called p16Ink4a is linked to bronchopulmonary dysplasia (BPD), a serious lung disease in premature babies. Researchers measured p16 levels in blood from 80 newborns and children, comparing those with and without BPD. The goal was to better understand the disease's causes, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help researchers understand why some premature babies develop long-term lung problems and point toward future treatments.
What could go wrong
This is a small, completed observational study that only measures biological markers, not a treatment. It may not lead to any direct medical advances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Mar 2018

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 15 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Premature(\< 28 GA) neonates * Alive neonate born at less than 28 gestational age * Signed inform consent Term neonates: * Alive neonate born at least at 37 GA or more * Signed inform consent Child from 7 to 15 years old with BPD: * Child from 7 to 15 years old * Child with a BPD diagnosed * Signed inform consent Child from 7 to 15 years old without BPD: * Child from 7 to 15 years old * Child receiving a blood test * Signed inform consent Exclusion Criteria: Premature (\< 28 GA) and term neonates: -Congenital malformation Child from 7 to 15 years old with BPD: * Cystic fibrosis * Evolutive cancer * Chronic inflammatory disease * Known anemia * Refusal of participation of child or parental authority Child from 7 to 15 years old without BPD: * Other respiratory disease: severe asthma, cystic fibrosis, deficit AAT, bronchial dilatation * Evolutive cancer * Chronic inflammatory disease * Known anemia * Refusal of participation of child or parental authority

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchopulmonary dysplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchopulmonary dysplasia

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, 94000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.